“…The mechanism of lung injury is not clear. As ATG is an antileukocyte antibody, the pathogenesis may be similar to that of transfusion-related lung injury (TRALI), or it may stem from its presence as a foreign protein [41,42]. BCNU may produce DILI within 6 weeks of administration or as late as 20 years after administration to treat pediatric cancers [43,44].…”